Insulet Corrects Omnipod® Pods; BTIG, Goldman See 52.8% and 33.3% Upsides
PODD•Insulet has initiated a voluntary correction for specific Omnipod® Pods in the US and other markets to address safety concerns. BTIG cut its price target to $235 and Goldman Sachs set one at $205, implying potential upsides of 52.8% and 33.3% from the current stock level.
1. Voluntary Omnipod® Pod Correction
Insulet has initiated a voluntary correction for specific lots of its Omnipod® Pods in the United States and international markets. The action targets product lots with potential issues to maintain device safety without a full recall.
2. Analyst Price Target Adjustments
Following the correction announcement, BTIG lowered its price target to $235 while Goldman Sachs set a $205 target. At the then trading price of $153.80, these adjustments imply upside potential of 52.8% and 33.3%, highlighting strong analyst confidence in long-term growth.
3. Valuation and Balance Sheet Strength
Insulet’s valuation ratios stand at a P/E of 33.04 and a price-to-sales ratio of 3.41, with an earnings yield of 3.03%. Its balance sheet shows a debt-to-equity ratio of 0.73 and a current ratio of 2.49, indicating solid liquidity and manageable debt levels.
